Background: The Prognostic Lung Fibrosis Consortium (PROLIFIC) was formed to develop well-qualified assays suitable for use as prognostic biomarkers within the context of clinical trials for Idiopathic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback